Trial Profile

A Clinicopathological Phase II Study of Axitinib in Patients With Advanced Angiosarcoma and Other Soft Tissue Sarcomas.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 12 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Axitinib (Primary)
Indications Haemangiosarcoma; Kaposi's sarcoma; Leiomyosarcoma; Soft tissue sarcoma; Synovial sarcoma
Focus Therapeutic Use
Acronyms Axi-STS

Most Recent Events

08 Sep 2023 Primary endpoint has been met. (Progression-free survival rate at 12 weeks after starting treatment, defined according to the Response Evaluation Criteria In Solid Tumours(RECIST criteria), as per Results published in the British Journal of Cancer
08 Sep 2023 Results published in the British Journal of Cancer
02 Mar 2019 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com